Alert SJ, Chon RI, Ropero TR, Valdés MJ, Reno CJ, Pérez TM, Forteza SM, García SD

Language: Spanish
References: 0
Page: e596
PDF size: 164.66 Kb.

ABSTRACT

Introduction: Tumors localized in the brainstem of children and adolescents entail a bad prognosis, especially those that are intrinsic and diffuse. With radiotherapy treatment, patients barely get a 15% of survival, and the numbers don’t improve with added chemotherapy.
Objectives: To estimate the effect of the association of radiotherapy treatment with Nimotuzumab monoclonal antibody in the survival of children and adolescents with brainstem tumors.
Method: Non randomized, analytical, longitudinal and prospective clinical study that was authorized by the National Regulatory Authority. There was studied a group of 46 patients aged from 2 to 18 years that suffered from intrinsic and diffuse brainstem tumors, from January 2008 (and in follow up) to March 2018. All the patients were treated with radiotherapy, with doses among 54 and 59,8 Grey, daily doses of 1,8 Grey, and from Monday to Friday. While they were under radiotherapy treatment, they get Nimotuzumab, in doses of 150 mg/m2 of corporal surface; then weekly doses of 8 shots; and finally, monthly doses during one or two years.
Results: In this group there was a survival mean of 18, 4 months, and an expected survival of 42, 9 % for 2 years and 35, 5 % for 5 years that can be stabilized to 10 years.
Conclusions: Combination of radiotherapy and Nimotuzumab monoclal antibody can increase the survival from brainstem tumors in children and adolescents.